Moody Capital Conference Presentation
CytoSorbents Executives to Present at Moody Capital Solutions Disruptive Growth Conference
Anonymous
CytoSorbents Corporation (NASDAQ: CTSO), a blood purification company, will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in New York on September 9-10. Market Screener reports that CEO Dr. Phillip Chan and CFO Peter Mariani will deliver an investor pitch and hold one-on-one meetings with institutional investors.
The company treats life-threatening conditions in intensive care units and cardiac surgery. Its flagship product, CytoSorb®, is approved across the European Union and sold in over 70 countries. CytoSorbents is also developing DrugSorb®, an anticlotting device using similar technology.
Blood Purification Technology Targets Critical Care
CytoSorbents specializes in removing harmful substances from patient blood during life-threatening crises. Market Screener describes the company as a leader in treating emergencies in ICUs and during heart surgery. The technology works by filtering toxins and inflammatory markers that damage organs during severe infections or sepsis.
CytoSorb® represents the company's core revenue driver. Approved in the EU, the device is now distributed globally across more than 70 markets. This international footprint positions CytoSorbents to capture growing demand as hospitals worldwide adopt blood purification for critical-care emergencies.
Pipeline Expansion Broadens Addressable Market
Beyond CytoSorb®, CytoSorbents is advancing DrugSorb®, which uses an anticlotting polymer design. This product targets a different clinical challenge: preventing dangerous blood clots during cardiac procedures. Expanding the pipeline allows the company to serve multiple patient populations and revenue streams.
The September conference gives investors direct access to leadership. One-on-one meetings with Dr. Chan and CFO Mariani allow institutional buyers to assess the company's growth strategy and competitive position. Moody Capital's event attracts biotech investors, venture firms, and public-market participants focused on disruptive innovation.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
10
Reach
10
A
AnonymousAuthor
